A phase II clinical trial demonstrated that monotherapy with the PARP inhibitor olaparib (AZD-2281; AstraZeneca) achieved encouraging response rates of 41% and 33% in patients with BRCA1- or BRCA2-mutated advanced breast and ovarian cancers, respectively [77]. The gene discussed is BRCA1; the disease is ovarian cancer.